NovoCure (BSP:N2VC34) Tariff Resilience Score: 5/10 (As of Jun. 25, 2026)


BSP:N2VC34 NovoCure Ltd BSP:N2VC34
46 GF Score
Price R$7.08
GF Value R$8.98
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is NovoCure Tariff Resilience Score?

NovoCure BSP:N2VC34 46 Tariff Resilience Score is 5 as of Jun. 25, 2026. GuruFocus rates BSP:N2VC34 with a GF Score™ of 46/100 and a GF Value™ of R$8.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 838 Medical Devices & Instruments companies, NovoCure ranks better than 79% on this metric.

NovoCure has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

NovoCure has Medical technology company with international sales and manufacturing. Faces tariff risks on imported components but can offset with pricing power and alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes NovoCure might have Average Resilient.

NovoCure  (BSP:N2VC34) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

NovoCure Tariff Resilience Score Related Terms

BSP:N2VC34 vs NEOG, ESTA, AXGN: Tariff Resilience Score Comparison

For the Medical Devices subindustry, NovoCure's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovoCure Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where NovoCure's Tariff Resilience Score falls into.


BSP:N2VC34
46GF Score
NovoCure Ltd BSP:N2VC34
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
NovoCure (BSP:N2VC34) has a Tariff Resilience Score of 5 as of Jun. 25, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, NovoCure ranks #176 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is NovoCure's Tariff Resilience Score too high?
NovoCure's current Tariff Resilience Score is 5. Based on the distribution chart, NovoCure ranks #176 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NovoCure has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Tariff Resilience Score compare to NEOG and ESTA?
According to the Medical Devices & Instruments industry distribution chart, NovoCure ranks #176 out of 838 companies for Tariff Resilience Score. This places NovoCure in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. NovoCure's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.98, compared to a current price of R$7.08 — trading 21.2% below its estimated fair value. The current Tariff Resilience Score is 5. NovoCure's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current Tariff Resilience Score is 5 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NovoCure (BSP:N2VC34) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of R$7.08 is trading 21.2% below its estimated GF Value™ of R$8.98. GuruFocus considers NovoCure to be Modestly Undervalued.

Key valuation signals for BSP:N2VC34:

  • Tariff Resilience Score: 5
  • GF Value™: R$8.98 vs. price of R$7.08 (21.2% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
46GF Score

Get the complete analysis for BSP:N2VC34

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$7.08
Price
R$8.98
GF Value